|
1
|
RECOVERY Collaborative Group. Horby P, Lim
WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N,
Brightling C, Ustianowski A, et al: Dexamethasone in hospitalized
patients with Covid-19. N Engl J Med. 384:693–704. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rodríguez-Tajes S, Miralpeix A, Costa J,
López-Suñé E, Laguno M, Pocurull A, Lens S, Mariño Z and Forns X:
Low risk of hepatitis B reactivation in patients with severe
COVID-19 who receive immunosuppressive therapy. J Viral Hepat.
28:89–94. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Aldhaleei WA, Alnuaimi A and Bhagavathula
AS: COVID-19 induced hepatitis B virus reactivation: A novel case
from the United Arab Emirates. Cureus. 12(e8645)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Baroiu L, Dumitru C, Iancu A, Leșe AC,
Drăgănescu M, Baroiu N and Anghel L: COVID-19 impact on the liver.
World J Clin Cases. 9:3814–3825. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Trifan A, Stanciu C, Iliescu L, Sporea I,
Baroiu L, Diculescu M, Luca MC, Miftode E, Cijeveschi C, Mihai C,
et al: Effectiveness of 8- and 12-week treatment with
ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naïve
HCV patients in a real-life setting in Romania: The AMETHYST study.
J Gastrointestin Liver Dis. 30:88–93. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chiu HY, Chiu YM, Chang Liao NF, Chi CC,
Tsai TF, Hsieh CY, Hsieh TY, Lai KL, Chiu TM, Wu NL, et al:
Predictors of hepatitis B and C virus reactivation in patients with
psoriasis treated with biologic agents: A 9-year multicenter cohort
study. J Am Acad Dermatol. 85:337–344. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Aygen B, Demir AM, Gumus M, Karabay O,
Kaymakoğlu S, Köksal AŞ, Köksal İ, Örmeci N and Tabak F:
Immunosuppressive therapy and the risk of hepatitis B reactivation:
Consensus report. Turk J Gastroenterol. 29:259–269. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
WHO: Global Hepatitis Report 2017.
https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
Accessed February 8, 2021.
|
|
9
|
Cannizzaro MV, Franceschini C, Esposito M,
Bianchi L and Giunta A: Hepatitis B reactivation in psoriasis
patients treated with anti-TNF agents: Prevention and management.
Psoriasis (Auckl). 7:35–40. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Snast I, Atzmony L, Braun M, Hodak E and
Pavlovsky L: Risk for hepatitis B and C virus reactivation in
patients with psoriasis on biologic therapies: A retrospective
cohort study and systematic review of the literature. J Am Acad
Dermatol. 77:88–97.e5. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gheorghe G, Pantea Stoian A, Gaman MA,
Socea B, Neagu TP, Stanescu AMA, Bratu OG, Mischianu DLD, Suceveanu
AI and Diaconu CC: The benefits and risks of antioxidant treatment
in liver diseases. Rev Chim. 70:651–655. 2019.
|
|
12
|
Lopes H, Baptista-Leite R, Franco D,
Eclemea I, Bratu EC, Furtunescu FL, Pop CS and Pana BC: Modeling
the puzzle of hepatitis C epidemiology in Romania: A pathway to
control. J Gastrointestin Liver Dis. 29:377–384. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Niculet E, Radaschin SD, Nastase F,
Draganescu M, Baroiu L, Miulescu M, Arbune M and Tatu AL: Influence
of phytochemicals in induced psoriasis (Review). Exp Ther Med.
20:3421–3424. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Calina D, Docea AO, Petrakis D, Egorov AM,
Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F,
Vinceti M, et al: Towards effective COVID-19 vaccines: Updates,
perspectives and challenges (Review). Int J Mol Med. 46:3–16.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tatu AL, Baroiu L, Fotea S, Anghel L,
Drima Polea E, Nadasdy T, Chioncel V and Nwabudike LC: A working
hypothesis on vesicular lesions related to COVID-19 infection,
koebner phenomena type V, and a short review of related data. Clin
Cosmet Investig Dermatol. 14:419–423. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Nwabudike LC and Tatu AL: Using
complementary and alternative medicine for the treatment of
psoriasis. A step in the right direction. JAMA Dermatol.
155(636)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nwabudike LC and Tatu AL: Response to:
‘Use of complementary and alternative medicine by patients with
psoriasis’. J Am Acad Dermatol. 81(e105)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Baroiu L, Beznea A, Plesea Condratovici C,
Onisor C, Grigore CA, Topor G and Rugină S: Comparative
Effectiveness of vancomycin and metronidazole for the initial
episode of nonsevere clostridium difficile infection, Rev. Chim.
70:3741–3745. 2019.
|
|
20
|
Pantea Stoian A, Pricop-Jeckstadt M, Pana
A, Ileanu BV, Schitea R, Geanta M, Catrinoiu D, Suceveanu AI,
Serafinceanu C, Pituru S, et al: Death by SARS-CoV 2: A Romanian
COVID-19 multi-centre comorbidity study. Sci Rep.
10(21613)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ancuceanu R, Dinu M, Furtunescu F and Boda
D: An inventory of medicinal products causing skin rash: Clinical
and regulatory lessons. Exp Ther Med. 18:5061–5071. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Stoian AP, Catrinoiu D, Rizzo M and
Ceriello A: Hydroxychloroquine, COVID-19 and diabetes. Why it is a
different story. Diabetes Metab Res Rev. 37(e3379)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Terrault NA, Bzowej NH, Chang KM, Hwang
JP, Jonas MM and Murad MH: American Association for the Study of
Liver Diseases. AASLD guidelines for treatment of chronic hepatitis
B. Hepatology. 63:261–283. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan
HL, Chen CJ, Chen DS, Chen HL, Chen J, Chien RN, et al:
Asian-Pacific clinical practice guidelines on the management of
hepatitis B: A 2015 update. Hepatol Int. 10:1–98. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
European Association For The Study Of The
Liver. EASL clinical practice guidelines: Management of chronic
hepatitis B virus infection. J Hepatol. 57:167–185. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Tatu AL, Elisei AM, Chioncel V, Miulescu M
and Nwabudike LC: Immunologic adverse reactions of β-blockers and
the skin. Exp Ther Med. 18:955–959. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Torsten Fredriksson: PASI score.
https://www.mdcalc.com/psoriasis-area-severity-index-pasi.
Accessed June 8, 2020.
|
|
28
|
Derm Calculator: DLQI score. http://www.dermcalculator.com/dlqi/. Accessed
June 8, 2020.
|
|
29
|
Calabrese LH, Zein NN and Vassilopoulos D:
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy
in rheumatic diseases: Assessment and preventive strategies. Ann
Rheum Dis. 65:983–989. 2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ilie MA, Caruntu C, Lixandru D, Tampa M,
Georgescu SR, Constantin MM, Constantin C, Neagu M, Zurac SA and
Boda D: In vivo confocal laser scanning microscopy imaging
of skin inflammation: Clinical applications and research
directions. Exp Ther Med. 17:1004–1011. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Batani A, Brănișteanu DE, Ilie MA, Boda D,
Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary
and microvascular parameters in psoriasis vulgaris using in vivo
reflectance confocal microscopy. Exp Ther Med. 15:1241–1246.
2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lee YH, Bae SC and Song GG: Hepatitis B
virus (HBV) reactivation in rheumatic patients with hepatitis core
antigen (HBV occult carriers) undergoing anti-tumor necrosis factor
therapy. Clin Exp Rheumatol. 31:118–121. 2013.PubMed/NCBI
|
|
33
|
Schurich A, Pallet LJ, Lubowiecki M, Singh
HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W and
Maini MK: The third signal cytokine IL-12 rescues the anti-viral
function of exhausted HBV-specific CD8 T cells. PLoS Pathog.
9(e1003208)2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zeuzem S and Carreño V: Interleukin-12 in
the treatment of chronic hepatitis B and C. Antiviral Res.
52:181–188. 2001.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bonifati C, Lora V, Graceffa D and Nosotti
L: Management of psoriasis patients with hepatitis B or hepatitis C
virus infection. World J Gastroenterol. 22:6444–6455.
2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chiu HY, Hui RC, Huang YH, Huang RY, Chen
KL, Tsai YC, Lai PJ, Wang TS and Tsai TF: Safety profile of
secukinumab in treatment of patients with psoriasis and concurrent
hepatitis B or C: A multicentric prospective cohort study. Acta
Derm Venereol. 98:829–834. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Combe B, Rahman P, Kameda H, Cañete JD,
Gallo G, Agada N, Xu W and Genovese MC: Safety results of
ixekizumab with 1822.2 patient-years of exposure: An integrated
analysis of 3 clinical trials in adult patients with psoriatic
arthritis. Arthritis Res Ther. 22(14)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Menter A, Strober BE, Kaplan DH,
Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro
KM, Davis DMR, et al: Joint AAD-NPF guidelines of care for the
management and treatment of psoriasis with biologics. J Am Acad
Dermatol. 80:1029–1072. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Teuwen LA, Geldhof V, Pasut A and
Carmeliet P: COVID-19: The vasculature unleashed. Nat Rev Immunol.
20:389–391. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Tatu AL, Nadasdy T and Bujoreanu FC:
Inflammation and vascular injury as the basis of COVID-19 skin
changes: Preliminary analysis of 23 patients from the literature
[Letter]. Clin Cosmet Investig Dermatol. 14:185–186.
2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Levi M: Tocilizumab for severe COVID-19: A
promising intervention affecting inflammation and coagulation. Eur
J Intern Med. 76:21–22. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sciascia S, Aprà F, Baffa A, Baldovino S,
Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, et
al: Pilot prospective open, single-arm multicentre study on
off-label use of tocilizumab in patients with severe COVID-19. Clin
Exp Rheumatol. 38:529–532. 2020.PubMed/NCBI
|
|
43
|
Niculet E, Chioncel V, Elisei AM, Miulescu
M, Buzia OD, Nwabudike LC, Craescu M, Draganescu M, Bujoreanu F,
Marinescu E, et al: Multifactorial expression of IL-6 with update
on COVID-19 and the therapeutic strategies of its blockade
(Review). Exp Ther Med. 21(263)2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Tocilizumab. LiverTox: Clinical and
research information on drug-induced liver injury [Internet].
Bethesda (MD): National Institute of Diabetes and Digestive and
Kidney Diseases, 2012. https://www.ncbi.nlm.nih.gov/books/NBK548243.
Accessed May 11, 2021.
|
|
45
|
Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH
and Dai L: Short-course tocilizumab increases risk of hepatitis B
virus reactivation in patients with rheumatoid arthritis: A
prospective clinical observation. Int J Rheum Dis. 20:859–869.
2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Sonneveld MJ, Murad SD, van der Eijk AA
and de Man RA: Fulminant liver failure due to hepatitis B
reactivation during treatment with tocilizumab. ACG Case Rep J.
6(e00243)2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wong GL, Wong VW, Yuen BW, Tse YK, Yip TC,
Luk HW, Lui GC and Chan HL: Risk of hepatitis B surface antigen
seroreversion after corticosteroid treatment in patients with
previous hepatitis B virus exposure. J Hepatol. 72:57–66.
2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Voicu DF, Anghel L, Baroiu L and Stan D:
About minimal hepatic encephalopathy. BRAIN. 11:70–77. 2020.
|
|
49
|
Luca L, Baroiu L, Ciubara AB, Anghel R,
Bulgaru-Iliescu AI, Anghel L and Ciubara A: Covid-19 and the
Spanish flu. From suffering to re-silience. BRAIN. 11:01–07.
2020.
|
|
50
|
Marin IM, Petropolou M, Baroiu L, Chirosca
AC, Anghel L and Luca L: Schizophrenia and the family burden during
the pandemic. BRAIN. 11:89–97. 2020.
|
|
51
|
Xu L, Liu J, Lu M, Yang D and Zheng X:
Liver injury during highly pathogenic human coronavirus infections.
Liver Int. 40:998–1004. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,
Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics
of 138 hospitalized patients with 2019 novel coronavirus-infected
pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma
CL, Li SB, Wang HY, Zhang S, Gao HN, et al: Clinical findings in a
group of patients infected with the 2019 novel coronavirus
(SARS-Cov-2) outside of Wuhan, China: Retrospective case series.
BMJ. 368(m606)2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Fan Z, Chen L, Li J, Cheng X, Yang J, Tian
C, Zhang Y, Huang S, Liu Z and Cheng J: Clinical features of
COVID-19-related liver functional abnormality. Clin Gastroenterol
Hepatol. 18:1561–1566. 2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y,
Li Z, Zhou G, Gou J, Qu J, et al: COVID-19: Abnormal liver function
tests. J Hepatol. 73:566–574. 2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Kunutsor SK and Laukkanen JA: Hepatic
manifestations and complications of COVID-19: A systematic review
and meta-analysis. J Infect. 81:e72–e74. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Mirzaie H, Vahidi M, Shokoohi M,
Darvishian M, Sharifi H, Sharafi H and Karamouzian M: COVID-19
among patients with hepatitis B or hepatitis C: A systematic
review. Hepat Mon. 20(e111617)2020.
|
|
58
|
Halichidis S, Dumea E and Cambrea CS:
Seroclearance of hepatitis B surface antigen after entecavir
treatment. J Gastrointestin Liver Dis. 22(236)2013.PubMed/NCBI
|
|
59
|
Liu J, Wang T, Cai Q, Sun L, Huang D, Zhou
G, He Q, Wang FS, Liu L and Chen J: Longitudinal changes of liver
function and hepatitis B reactivation in COVID-19 patients with
pre-existing chronic hepatitis B virus infection. Hepatol Res.
50:1211–1221. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Lu J, Hu M, Zhou X, Zhu H, Wang F, Huang
J, Guo Z, Li Q, Yin Q and Yang Z: Clinical Characteristics and
outcomes in HBV carriers with COVID-19 in Wuhan, China: A
retrospective cohort study. Res Sq. 2–17. 2020.
|
